Foghorn Therapeutics

Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. It is discovering and developing a novel class of precision medicine therapeutics targeting the chromatin regulatory system in oncology. Through its scalable Gene Traffic Control product platform, the firm is systematically interrogating and drugging the chromatin regulatory system. The company was founded by Cigall Kadoch, Gerald W. Crabtree and Douglas G. Cole in October 2015 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

• Dose escalation in FHD-286 combination study in AML continues to progress; clinical data anticipated in the second half of 2024

Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook

Poster presentation of FHD-909, a first-in-class oral BRM selective inhibitor, highlighting preclinical efficacy and safety in multiple mouse models of NSCLC; IND filing planned in Q2 2024

Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909

CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that it will participate in Cowen's 44th Annual Health Care Conference, which is taking place on March 4–6, 2024, at the Boston Marriott Copley Place in Boston, MA. With an initial focus in oncology, Foghorn's Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.

Foghorn Therapeutics to Participate in Cowen's 44th Annual Health Care Conference

Foghorn Therapeutics Inc. (FHTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Foghorn Therapeutics Inc. (FHTX) Moves 22.7% Higher: Will This Strength Last?

Foghorn (FHTX) gains 55% as its strategic collaboration partner, Lilly, selects the pre-clinical candidate, FHD-909, for clinical development.

Foghorn (FHTX) Jumps 55% as Lilly Takes Up FHD-909 Development

Foghorn Therapeutics Inc. (FHTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Foghorn Therapeutics Inc. (FHTX) Upgraded to Buy: Here's Why

The average of price targets set by Wall Street analysts indicates a potential upside of 160.6% in Foghorn Therapeutics Inc. (FHTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

How Much Upside is Left in Foghorn Therapeutics Inc. (FHTX)? Wall Street Analysts Think 160.57%

CAMBRIDGE, Mass., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that clinical data from the Phase 1 dose escalation study of FHD-286 in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) will be presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, to be held December 9-12, 2023, in San Diego, California.

Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM Inhibitor, in Patients with Advanced Hematologic Malignancies, to be Presented at American Society of Hematology Annual Meeting

CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today provided a financial and corporate update in conjunction with the Company's 10-Q filing for the quarter ended September 30, 2023. With an initial focus in oncology, Foghorn's Gene Traffic Control® Platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.

Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update

CAMBRIDGE, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that clinical data from the dose escalation and expansion study of FHD-286 in metastatic uveal melanoma (mUM) will be presented at the ESMO Congress 2023, to be held October 20–24 in Madrid, Spain.

Foghorn Therapeutics Announces Clinical Data From Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma to Be Presented at ESMO Congress

CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that new clinical and pre-clinical data for its BRG1/BRM inhibitor FHD-286, pre-clinical data for its selective EP300 program, and pre-clinical data for its BRD9 degrader FHD-609, will be presented at the AACR-NCI-EORTC International Conference. The conference will be held October 11–15, 2023, in Boston, Massachusetts.

Foghorn Therapeutics to Present Clinical and Pre-Clinical Data from Multiple Programs Across Its Diverse Pipeline at AACR-NCI-EORTC International Conference

Denali Therapeutics

Seres Therapeutics

Moderna

Omega Therapeutics

Sana Biotechnology

CAMBRIDGE, Mass. , Sept. 11, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today the appointment of Amanda Kay as Senior Partner and Chief Business Development Officer.

Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer

CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious disease by correcting abnormal gene expression, today announced the first patient has been dosed in the Phase 1 study of FHD-286 in combination with decitabine or cytarabine in relapsed and/or refractory acute myelogenous leukemia (AML).

Foghorn Therapeutics Announces First Patient Dosed in Phase 1 Combination Study of FHD-286 for Relapsed and/or Refractory AML

Foghorn Therapeutics Inc. stock has increased by 70% in the last 4 months after a clinical hold on their lead program was lifted. Foghorn's technology, called "gene traffic control," aims to regulate gene expression by targeting chromatin in the chromatin gene regulatory system. The company faced setbacks with clinical holds and program cancellations, including a patient death and poor phase 1 data for their uveal melanoma program.

Foghorn Therapeutics: Ifs, Buts, And Clinical Holds

Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.70 per share versus the Zacks Consensus Estimate of a loss of $0.73. This compares to loss of $0.66 per share a year ago.

Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Misses Revenue Estimates

— Initiating FHD-286 combination study in AML in the third quarter of 2023 — Selective BRM, ARID1B, EP300, and CBP, targeting key regulators of gene expression, continue to advance toward IND — Cash, cash equivalents, and marketable securities of $284.3 million, as of June 30, 2023, provides cash runway into the second half of 2025 CAMBRIDGE, Mass., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today provided a financial and corporate update in conjunction with the Company's 10-Q filing for the quarter ended June 30, 2023.

Foghorn Therapeutics Provides Second Quarter 2023 Financial and Corporate Update

Foghorn Therapeutics Inc. (FHTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Foghorn Therapeutics Inc. (FHTX) Surges 12.8%: Is This an Indication of Further Gains?

- Clinical data support safety and tolerability profile of FHD-286, a highly potent, - selective, allosteric, oral, small molecule inhibitor of BRG1/BRM - Clinical activity observed in late-line metastatic uveal melanoma includes nine patients with stable disease and one patient with a confirmed partial response - Foghorn does not plan to advance FHD-286 in uveal melanoma - Foghorn anticipates initiating a FHD-286 combination study in relapsed/refractory AML during the third quarter of 2023 CAMBRIDGE, Mass., June 28, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious disease by correcting abnormal gene expression, today announced data from the Phase 1 dose escalation safety study of FHD-286 in metastatic uveal melanoma (mUM).

Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma

Empress's Chemilogics™ product platform creates small molecule drugs quickly and cost-effectively The company emerges after two years of platform development with an initial commitment of $50 million from Flagship Pioneering Empress has identified and characterized 15 potential small molecule drugs in less than two years; it expects to file multiple Investigational New Drug (IND) applications within the next 24 months Murray McKinnon, Ph.D., former Global Head of J&J's World Without Disease Accelerator and Head of Immunology Discovery within Janssen Pharmaceuticals, appointed Chief Scientific Officer CAMBRIDGE, Mass.

Flagship Pioneering Unveils Empress Therapeutics to Revolutionize Drug Discovery by Applying the Power of Genetics to Identify Small Molecule Drugs

CAMBRIDGE, Mass., June 07, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced management's participation in the following investor conferences in June 2023. With an initial focus in oncology, Foghorn's Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.

Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences

- Plan to Initiate a Phase 1 Study of FHD-286 in Combination with Decitabine or Cytarabine in Relapsed and/or Refractory AML Patients in Q3'2023

Foghorn Therapeutics Announces FDA Has Lifted Clinical Hold on Phase 1 Study of FHD-286 in Relapsed and/or Refractory AML/MDS Patients

NEW YORK , May 10, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Foghorn Therapeutics Inc. ("Foghorn" or the "Company") (NASDAQ: FHTX). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX

Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to loss of $0.65 per share a year ago.

Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Lags Revenue Estimates

CAMBRIDGE, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today provided a financial and corporate update in conjunction with the Company's 10-Q filing for the quarter ended March 31, 2023. With an initial focus in oncology, Foghorn's Gene Traffic Control® Platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.

News for Foghorn Therapeutics Stock (FHTX)